Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication

Molecules

Volumn 16, Issue 1, 2011, Pages 202-220

  Li, Bing ^a   Peet, Norton P ^a   Butler, Michelle M ^a   Burnett, James C ^b   Moir, Donald T ^a   Bowlin, Terry L ^a  

^a MICROBIOTIX INC   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Botulinum neurotoxin; Drug discovery; Inhibitor

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; EXOCYTOSIS; HUMAN; METABOLISM; NEUROMUSCULAR SYNAPSE; PROTEIN CONFORMATION; REVIEW; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINE; ANIMALS; BOTULINUM TOXINS; CRYSTALLOGRAPHY, X-RAY; EXOCYTOSIS; HUMANS; MODELS, MOLECULAR; NEUROMUSCULAR JUNCTION; PROTEIN CONFORMATION;

EID: 79251532110     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16010202     Document Type: Review

References (92)

1. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059-1070. (Pubitemid 32176420)
2. Paddle, B. M. Therapy and prophylaxis of inhaled biological toxins. J. Appl. Toxicol. 2003, 23, 139-170.
3. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefense: Therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 2005, 4, 281-297.
4. Burnett, J. C.; Schmidt, J. J.; McGrath, C. F.; Nguyen, T. L.; Hermone, A. R.; Panchal, R. G.; Vennerstrom, J. L.; Kodukula, K.; Zaharevitz, D. W.; Gussio, R.; Bavari, S. Conformational sampling of the botulinum neurotoxin serotype A light chain: Implications for inhibitor binding. Bioorg. Med. Chem. 2005, 13, 333-341.
5. Josko, D. Botulin toxin: A weapon in terrorism. Clin. Lab. Sci. 2004, 17, 30-34.
6. Clarke, S. C. Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins. Br. J. Biomed. Sci. 2005, 62, 40-46.
7. Hicks, R. P.; Hartell, M. G.; Nichols, D. A.; Bhattacharjee, A. K.; van Hamont, J. E. Skillman, D. R. The medicinal chemistry of botulinum, ricin and anthrax toxins. Curr. Med. Chem. 2005, 12, 667-690.
8. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefense: Therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 2005, 4, 281-297.
9. Shukla, H. D.; Sharma, S. K. Clostridium botulinum: A bug with beauty and weapon. Crit. Rev. Microbiol. 2005, 31, 11-18.
10. Comella, C. L.; Pullman, S. L. Botulinum toxins in neurological disease. Muscle Nerve 2004, 29, 628-644.
11. Glogau, R. G. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin. J. Pain 2002, 18 (6 Suppl.), S191-S197.
12. Marks, J. D. Medical aspects of biologic toxins. Anesthesiol. Clin. N. Amer. 2004, 22, 509-532.
13. Montecucco, C.; Molgo, J. Botulinal neurotoxins: Revival of an old killer. Curr. Opin. Pharmacol. 2005, 5, 274-279.
14. Bhidayasiri, R.; Truong, D. D. Expanding use of botulinum toxin. J. Neurol. Sci. 2005, 235, 1-9.
15. Bigalke, H.; Rummel, A. Medical aspects of toxin weapons. Toxicology 2005, 214, 210-220.
16. Foster, K. A. A new wrinkle on pain relief: Re-engineering clostridial neurotoxins for analgesics. Drug Discov. Today 2005, 10, 563-569.
17. Cote, T. R.; Mohan, A. K.; Polder, J. A.; Walton, M. K.; Braun, M. M. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol. 2005, 53, 407-415.
18. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059-1070. (Pubitemid 32176420)
19. Foran, P. G.; Mohammed, N.; Lisk, G. O.; Nagwaney, S.; Lawrence, G. W.; Johnson, E.; Smith, L.; Aoki, K. R.; Dolly, J. O. Evaluation of the therapeutic usefulness of botulinum neurotoxins B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278, 1363-1371.
20. Greenfield, R. A.; Brown, B. R.; Hutchins, J. B.; Iandolo, J. J.; Jackson, R.; Slater, L. N.; Bronze, M. S. Microbiological, biological, and chemical weapons of warfare and terrorism. Am. J. Med. Sci. 2002, 323, 326-340.
21. Rosenbloom, M.; Leikin, J. B.; Vogel, S. N.; Chaudry, Z. A. Biological and chemical agents: A brief synopsis. Am. J. Ther. 2002, 9, 5-14.
22. Meunier, F. A.; Lisk, G.; Sesardic, D.; Dolly, J. O. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 2003, 22, 454-466.
23. Lacy, D. B.; Tepp, W.; Cohen, A. C.; DasGupta, B. R.; Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
24. Simpson, L. L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 167-193.
25. Singh, B. R. Intimate details of the most poisonous poison. Nat. Struct. Biol. 2000, 7, 617-619.
26. Turton, K.; Chaddock, J. A.; Acharya, K. R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552-558.
27. Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Sudhof, T. C.; Jahn, R.; Niemann, H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 1994, 269, 1617-1620.
28. Schmidt, J. J.; Stafford, R. G. Fluorogenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol. 2003, 69, 297-303.
29. Schiavo, G.; Malizio, C.; Trimble, W. S.; Polverino de Laureto, P.; Milan, G.; Sugiyama, H.; Johnson, E. A.; Montecucco, C. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J. Biol. Chem. 1994, 269, 20213-20216.
30. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; de Polverino, L. P.; DasGupta, B. R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-835.
31. Schiavo, G.; Rossetto, O.; Catsicas, S.; de Polverino, L. P.; DasGupta, B. R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 1993, 268, 23784-23787.
32. Schiavo, G.; Shone, C. C.; Rossetto, O.; Alexander, F. C.; Montecucco, C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 1993, 268, 11516-11519.
33. Blasi, J.; Chapman, E. R.; Yamasaki, S.; Binz, T.; Niemann, H.; Jahn, R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO. J. 1993, 12, 4821-4828.
34. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 693-699. (Pubitemid 30636683)
35. Kumaran, D.; Eswaramoorthy, S.; Furey, W.; Navaza, J.; Sax, M.; Swaminathan, S. Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation. J. Mol. Biol. 2009, 386, 233-245.
36. Zuniga, J. E.; Schmidt, J. J.; Fenn, T.; Burnett, J. C.; Arac, D.; Gussio, R.; Stafford, R. G.; Badie, S. S.; Bavari, S.; Brunger, A. T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than the SNAP-25 substrate. Structure 2008, 16, 1588-1597.
37. Silvaggi, N. R.; Wilson, D.; Tzipori, S.; Allen, K. N. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 2008, 47, 5736-5745.
38. Breidenbach, M. A.; Brunger, A. T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432, 925-929.
39. Hanson, M. A.; Stevens, R. C. Co-crystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution. Nat. Struct. Biol. 2000, 7, 687-692.
40. Agarwal, R.; Eswaramoorthy, S.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 2004, 43, 6637-6644.
41. Agarwal, R.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry 2005, 44, 11758-11765.
42. Arndt, J. W.; Yu, W.; Bi, F.; Stevens, R. C. Crystal structure of botulinum neurotoxin type G light chain: Serotype divergence in substrate recognition. Biochemistry 2005, 44, 9574-9580.
43. Arndt, J. W.; Chai, Q.; Christian, T.; Stevens, R. C. Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity. Biochemistry 2006, 45, 3255-3262.
44. Montecucco, C.; Schiavo, G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 1995, 28, 423-472.
45. Krieglstein, K. G.; DasGupta, B. R.; Henschen, A. H. Covalent structure of botulinum neurotoxin type A: Location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Protein. Chem. 1994, 13, 49-57.
46. Sagane, Y.; Watanabe, T.; Kouguchi, H.; Sunagawa, H.; Inoue, K.; Fujinaga, Y.; Oguma, K.; Ohyama, T. Dichain structure of botulinum neurotoxin: Identification of cleavage sites in types C, D, and F neurotoxin molecules. J. Protein. Chem. 1999, 18, 885-892.
47. Gul, N.; Smith, L. A.; Ahmed, S. A. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PLoS One 2010, 5, e12872.
48. Schiavo, G.; Shone, C. C.; Bennett, M. K.; Scheller, R. H.; Montecucco, C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J. Biol. Chem. 1995, 270, 10566-10570.
49. Lebeda, F. J.; Cer, R. Z.; Mudunuri, U.; Stephens, R.; Singh, B. R.; Alder, M. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins 2010, 2, 978-997.
50. Hicks, R. P.; Hartell, M. G.; Nichols, D. A.; Bhattacharjee, A. K.; van Hamont, J. E.; Skillman, D. R. The medicinal chemistry of botulinum, ricin and anthrax toxins. Curr. Med. Chem. 2005, 12, 667-690.
51. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K. D. The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. Angew. Chem. Int. Ed. 2008, 47, 8360-8379.
52. Burnett, J. C.; Schmidt, J. J.; Stafford, R. G.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Vennerstrom, J. L.; McGrath, C. F.; Lane, D. J.; Sausville, E. A.; Zaharevitz, D. W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 2003, 310, 84-93.
53. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Solaja, B. A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinolinebased inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50, 2127-2136.
54. Li, B.; Pai, R.; Cardinale, S. C.; Butler, M. M.; Peet, N. P.; Moir, D. T.; Bavari, S.; Bowlin, T. L. Synthesis and biological evaluation of botulinum neurotoxin A protease inhibitors. J. Med. Chem. 2010, 53, 2264-2276.
55. Silvaggi, N. R.; Boldt, G. E.; Hixon, M. S.; Kennedy, J. P.; Tzipori, S.; Janda, K. D.; Allen, K. N. Structures of clostridium botulinum neurotoxin serotype A light chain complexed with smallmolecule inhibitors highlight active-site flexibility. Chem. Biol. 2007, 14, 533-542.
56. Schmidt, J. J.; Bostian, K. A. Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem. 1995, 14, 703-708.
57. Cardinale, S. C.; Butler, M. M.; Ruthel, G.; Nuss, J. E.; Wanner, L. M.; Li, B.; Pai, R.; Peet, N. P.; Bavari, S.; Bowlin, T. L. Novel benzimidazole inhibitors of botulinum neurotoxin/A display enzyme and cell based potency. The Botulinum J. 2010, in press.
58. Park, J. B.; Simpson, L. L. Progress toward development of an inhalation vaccine against botulinum toxin. Expert Rev. Vaccines 2004, 3, 477-487.
59. Byrne, M. P.; Smith, L. A. Development of vaccines for prevention of botulism. Biochimie 2000, 82, 955-966.
60. Nowakowski, A.; Wang, C.; Powers, D. B.; Amersdorfer, P.; Smith, T. J.; Montgomery, V. A.; Sheridan, R.; Blake, R.; Smith, L. A.; Marks, J. D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 2002, 99, 11346-11350.
61. Rummel, A.; Karnath, T.; Henke, T.; Bigalke, H.; Binz, T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 2004, 279, 30865-30870.
62. Dong, M.; Richards, D. A.; Goodnough, M. C.; Tepp, W. H.; Johnson, E. A.; Chapman, E. R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 2003, 162, 1293-1303.
63. Bakry, N.; Kamata, Y.; Simpson, L. L. Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J. Pharmacol. Exp. Ther. 1991, 258, 830-836.
64. Li, P.-Z.; Zhou, J.; Miao, W.-Y.; Ding, F.-H.; Meng, J.-Y.; Jia, G.-R.; Li, J.-F.; Ye, H.-J.; He, X.-Y.; Chen, M.-Y.; Huang, Z.-M. Therapeutic effect of toosendanin on animal botulism. Tradit. Herb. Drugs 1982, 13, 28-30.
65. Shi, Y.-L.; Li, M.-F. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog. Neurobiol. 2007, 82, 1-10.
66. Shi, Y.-L.; Wang, Z.-F. Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol. Sin. 2004, 25, 839-848.
67. Zou, J.; Miao, W.-Y.; Ding, F.-H.; Meng, J.-Y.; Ye, H.-J.; Jia, G.-R.; He, X.-Y.; Sun, G.-Z.; Li, P.-Z. The effect of toosendanin on monkey botulism. J. Tradit. Chin. Med. 1985, 5, 29-30.
68. Fischer, A.; Nakai, Y.; Eubanks, L. M.; Clancy, C. M.; Tepp, W. H.; Pellett, S.; Dickerson, T. J.; Johnson, E. A.; Janda, K. D.; Montal, M. Bimodal modulation of the botulinum neurotoxin proteinconducting channel. Proc. Natl. Acad. Sci. USA 2009, 106, 1330-1335.
69. Nakai, Y.; Tepp, W. H.; Dickerson, T. J.; Johnson, E. A.; Janda, K. D. Function-oriented synthesis applied to the anti-botulinum natural product toosendanin. Bioorg. Med. Chem. 2009, 17, 1152-1157.
70. Nakai, Y.; Pellett, S.; Tepp, W. H.; Johnson, E. A.; Janda, K. D. Toosendanin: Synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). Bioorg. Med. Chem. 2010, 18, 1280-1287.
71. Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 2008, 41, 40-49.
72. Simpson, L. L. The interaction between aminoquinolines and presynaptically acting neurotoxins. J. Pharmacol. Exp. Ther. 1982, 222, 43-48.
73. Simpson, L. L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J. Pharmacol. Exp. Ther. 1983, 225, 546-552.
74. Simpson, L. L.; Coffield, J. A.; Bakry, N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1994, 269, 256-262.
75. Eubanks, L. M.; Silhar, P.; Salzameda, N. T.; Zakhari, J. S.; Xiaochuan, F.; Barbieri, J. T.; Shoemaker, C. B.; Hixon, M. S.; Janda, K. D. Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. ACS Med. Chem. Lett. 2010, 1, 268-272.
76. Silhar, P.; Capkova, K.; Salzameda, N. T.; Barbieri, J. T.; Hixon, M. S.; Janda, K. D. Botulinum neurotoxin A protease: Discovery of natural product exosite inhibitors. J. Am. Chem. Soc. 2010, 132, 2868-2869.
77. Stowe, G. N.; Silhar, P.; Hixon, M. S.; Silvaggi, N. R.; Allen, K. N.; Moe, S. T.; Jacobson, A. R.; Barbieri, J. T.; Janda, K. D. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Org. Lett. 2010, 12, 756-759.
78. Moe, S. T.; Thompson, A. B.; Smith, G. M.; Fredenburg, R. A.; Stein, R. L.; Jacobson, A. R. Botulinum neurotoxin serotype A inhibitors: Small molecule mercaptoacetamide analogs. Bioorg. Med. Chem. 2009, 17, 3072-3079.
79. Burnett, J. C.; Ruthel, G.; Stegmann, C. M.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Stafford, R. G.; Lane, D. J.; Kenny, T. A.; McGrath, C. F.; Wipf, P.; Stahl, A. M.; Schmidt, J. J.; Gussio, R.; Brunger, A. T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 2007, 282, 5004-5014.
80. Burnett, J. C.; Wang, C.; Nuss, J. E.; Nguyen, T. L.; Hermone, A. R.; Schmidt, J. J.; Gussio, R.; Wipf, P.; Bavari, S. Pharmacophore-guided lead optimization: The rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype A metalloprotease. Bioorg. Med. Chem. Lett. 2009, 19, 5811-5813.
81. Wang, C.; Widom, J.; Petronijevic, F.; Burnett, J. C.; Nuss, J. E.; Bavari, S.; Gussio, R.; Wipf, P. Synthesis and biological evaluation of inhibitors of botulinum neurotoxin metalloprotease. Heterocycles 2009, 79, 487-520.
82. Butler, M. M.; Cardinale, S. C.; Li, B.; Pai, R.; Ruthel, G.; Nuss, J. E.; Wanner, L. M.; Park, J.-B.; Rich, C.; Basu, A.; Mills, D.; Williams, J. D.; Peet, N. P.; Moir, D.; Bavari, S.; Bowlin, T. L. Unpublished results.
83. Roxas-Duncan, V.; Enyedy, I.; Montgomery, V. A.; Eccard, V. S.; Carrington, M. A.; Lai, H.; Gul, N.; Yang, D. C. H.; Smith, L. A. Identification and biochemical characterization of small molecule inhibitors of clostridium botulinum neurotoxin seroptype A. Antimicro. Agents Chemother. 2009, 53, 3478-3486.
84. Lai, H.; Feng, M.; Roxas-Duncan, V.; Dakshanamurthy, S.; Smith, L. A.; Yang, D. C. H. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: Effects of zinc ion and peptides on inhibition. Arch. Biochem. Biophys. 2009, 491, 75-84.
85. Pang, Y.-P.; Vummenthala, A.; Mishra, R. K.; Park, J. G.; Wang, S.; Davis, J.; Millard, C. B.; Schmidt, J. J. Potent new small molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLos One 2009, 4, e7730.
86. Pang, Y.-P.; Davis, J.; Wang, S.; Park, J. G.; Nambiar, M. P.; Schmidt, J. J.; Millard, C. B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS One 2010, 5, e10129.
87. Hermone, A. R.; Burnett, J. C.; Nuss, J. E.; Tressler, L. E.; Nguyen, T. L.; Solaja, B. A.; Vennerstrom, J. L.; Schmidt, J. J.; Wipf, P.; Bavari, S.; Gussio, R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem 2008, 3, 1905-1912.
88. Nuss, J. E.; Dong, Y.; Wanner, L. M.; Ruthel, G.; Wipf, P.; Gussio, R.; Vennerstrom, J. L.; Bavari, S.; Burnett, J. C. Pharmacophore refinement guides the rational design of nanomolar-range inhibitors of the botulinum neurotoxin serotype A metalloprotease. ACS Med. Chem. Lett. 2010, 1, 301-305.
89. Solaja, B. A.; Opsenica, D.; Smith, K. S.; Milhous, W. K.; Terzic, N.; Opsenica, I.; Burnett, J. C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J. Med. Chem. 2008, 51, 4388-4391.
90. Capkova, K.; Hixon, M. S.; Pellett, S.; Barbieri, J. T.; Johnson, E. A.; Janda, K. D. Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase. Bioorg. Med. Chem. Lett. 2009, 20, 206-208.
91. Eswaramoorthy, S.; Kumaran, D.; Swaminathan, S. A novel mechanism for clostridium botulinum neurotoxin inhibition. Biochemistry 2002, 41, 9795-9802.
92. Adler, M.; Nicholson, J. D.; Cornille, F.; Hackley, B. E., Jr. Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett. 1998, 429, 234-238.